Vimarsana
Biggest News Aggregation in the World

Improving Global News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Improving Global. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Improving Global Today - Breaking & Trending Today

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) - Vimarsana News

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...

Advances in the management of chronic kidney disease - Vimarsana News

Advances in the management of chronic kidney disease

Chronic kidney disease (CKD) represents a global public health crisis, but awareness by patients and providers is poor. Defined as persistent abnormalities in kidney structure or function for more than three months, manifested as either low glomerular filtration rate or presence of a marker of kidney damage such as albuminuria, CKD can be identified through readily available blood and urine tests. Early recognition of CKD is crucial for harnessing major advances in staging, prognosis, and treatment. This review discusses the evidence behind the general principles of CKD management, such as blo...

Source: bmj.com
New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with - Vimarsana News

New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with

FIGARO-BM, an exploratory human biomarker study, provides additional insight on finerenone's mechanism of action in blocking mineralocorticoid receptor (MR) overactivation1New data presented at the American Society of Nephrology’s (ASN) Kidney Week 2023WHIPPANY, N.J.--(BUSINESS WIRE)--At the American Society of Neph...